A pharmaceutical company accused of suppressing negative studies of its anti-depressant drugs has agreed to publish all information from its clinical trials, writes Craig Kenny.

GlaxoSmithKline also agreed to pay $2.5m in a settlement with New York State Attorney General Eliot Spitzer.

GSK had already agreed to publish information about its drug Seroxat, following allegations that studies suggesting links with suicidal thoughts in children were suppressed. It will now publish all its drug trial data since December 2000 on the internet.

GSK insisted the charges were unfounded but said it had settled the case to avoid the cost of protracted litigation.